Precipio Inc
NASDAQ:PRPO

Watchlist Manager
Precipio Inc Logo
Precipio Inc
NASDAQ:PRPO
Watchlist
Price: 30.7 USD 9.66% Market Closed
Market Cap: $54.6m

Precipio Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Precipio Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Precipio Inc
NASDAQ:PRPO
Free Cash Flow
$359k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Free Cash Flow
$1.3B
CAGR 3-Years
15%
CAGR 5-Years
-9%
CAGR 10-Years
7%
CVS Health Corp
NYSE:CVS
Free Cash Flow
$7.8B
CAGR 3-Years
-17%
CAGR 5-Years
-10%
CAGR 10-Years
3%
Cigna Corp
NYSE:CI
Free Cash Flow
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Free Cash Flow
$1.2B
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
5%
Guardant Health Inc
NASDAQ:GH
Free Cash Flow
-$233.1m
CAGR 3-Years
16%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

Precipio Inc
Glance View

Market Cap
54.6m USD
Industry
Health Care

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in Omaha, Nebraska and currently employs 55 full-time employees. The company went IPO on 2000-07-18. The firm is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha.

PRPO Intrinsic Value
11.09 USD
Overvaluation 64%
Intrinsic Value
Price $30.7

See Also

What is Precipio Inc's Free Cash Flow?
Free Cash Flow
359k USD

Based on the financial report for Dec 31, 2025, Precipio Inc's Free Cash Flow amounts to 359k USD.

What is Precipio Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
66%

Over the last year, the Free Cash Flow growth was 66%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett